NASDAQ:APVO

Aptevo Therapeutics Stock Forecast, Price & News

$32.51

-1.31 (-3.87 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$32.47

Now: $32.51▼

$34.36

50-Day Range

$33.82

MA: $39.69▼

$47.76

52-Week Range

$2.94

Now: $32.51▼

$60.00

Volume73,344 shs

Average Volume74,050 shs

Market Capitalization$142.39 million

P/E RatioN/A

Dividend YieldN/A

Beta7.47

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

MarketRank^™

Overall MarketRank^™

1.24 out of 5 stars

Medical Sector

670th out of 1,558 stocks

Pharmaceutical Preparations Industry

340th out of 638 stocks

1.5 Analyst's Opinion

Consensus Rating
Aptevo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.00, Aptevo Therapeutics has a forecasted downside of 1.6% from its current price of $32.51.
Amount of Analyst Coverage
Aptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Aptevo Therapeutics has received 187 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aptevo Therapeutics has received 199 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aptevo Therapeutics has received 51.55% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote “Outperform” if you believe APVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aptevo Therapeutics does not currently pay a dividend.
Dividend Growth
Aptevo Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptevo Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,097,602.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.88% of the stock of Aptevo Therapeutics is held by insiders.
Percentage Held by Institutions
Only 14.06% of the stock of Aptevo Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($8.78) to ($5.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptevo Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptevo Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptevo Therapeutics has a P/B Ratio of 8.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:APVO

Previous Symbol

CUSIPN/A

CIK1671584

Webwww.aptevotherapeutics.com

Phone206-838-0500

Employees80

Debt

Debt-to-Equity Ratio11.44

Current Ratio4.13

Quick Ratio4.13

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$32.42 million

Price / Sales4.39

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.66 per share

Price / Book8.88

Profitability

EPS (Most Recent Fiscal Year)($15.27)

Net Income$-40,450,000.00

Net MarginsN/A

Return on Equity-345.40%

Return on Assets-97.13%

Miscellaneous

Outstanding Shares4,380,000

Market Cap$142.39 million

Next Earnings Date3/24/2021 (Estimated)

OptionableOptionable

$32.51

-1.31 (-3.87 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

How has Aptevo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APVO stock has increased by 7,640.5% and is now trading at $32.51.
View which stocks have been most impacted by COVID-19.

Is Aptevo Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aptevo Therapeutics?

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($2.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.05) by $0.10. The biotechnology company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.49 million.
View Aptevo Therapeutics' earnings history.

What price target have analysts set for APVO?

2 brokerages have issued 12-month price targets for Aptevo Therapeutics' stock. Their forecasts range from $32.00 to $32.00. On average, they anticipate Aptevo Therapeutics' share price to reach $32.00 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Aptevo Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 165,800 shares, a decline of 40.1% from the December 15th total of 276,700 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company's stock are short sold.
View Aptevo Therapeutics' Short Interest.

Who are some of Aptevo Therapeutics' key competitors?

Some companies that are related to Aptevo Therapeutics include Five Prime Therapeutics (FPRX), Pandion Therapeutics (PAND), SIGA Technologies (SIGA), Xenon Pharmaceuticals (XENE), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Atreca (BCEL), Prothena (PRTA), Neoleukin Therapeutics (NLTX), IVERIC bio (ISEE), Molecular Templates (MTEM), BioVie (BIVI), Spectrum Pharmaceuticals (SPPI), Aldeyra Therapeutics (ALDX) and RAPT Therapeutics (RAPT).
View all of APVO's competitors.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:

Mr. Marvin L. White, Pres, CEO & Director (Age 59, Pay $779.77k)
Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 55, Pay $533.81k)
Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 64, Pay $485.68k)
Ms. Stacey Jurchison, Sr. Director of Investor Relations & Corp. Communications
Ms. Heather Boussios, Acting Gen. Counsel & Assistant Sec.
Ms. Censia Pottorf, VP of HR

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $32.51.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $142.39 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 80 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here